BRIEF-Merck's phase iii tailor landmark study demonstrates significant benefits of Erbitux in combination with FOLFOX over FOLFOX alone
April 25, 2016 at 03:17 AM EDT
* Says phase iii tailor landmark study demonstrates significant benefits of erbitux in combination with FOLFOX over FOLFOX alone
